Pregnancy clock proteins for predicting due date and time to birth

A method of determining the estimated due date (EDD) or time to birth (TTB) for a pregnant female, the method comprising:

• (a) detecting the presence or amount of a pair of isolated biomarkers in a biological sample obtained from a pregnant female;
• and
• (b) measuring in said biological sample a reversal value for said pair of isolated biomarkers,
• wherein said reversal value predicts the EDD or TTB for said pregnant female in a predictive model,
• wherein detecting comprises subjecting said biological sample to:
• (i) a proteomics work-flow comprised of mass spectrometry (MS) quantification:
• or (ii) an assay that utilizes a capture agent that binds to at least one biomarker of said pair of isolated biomarkers,
• wherein said biological sample is selected from the group consisting of whole blood, plasma, and serum, and
• wherein said pair of isolated biomarkers comprises Disintegrin and metalloproteinase domain-containing protein 12 (ADA12) and an isolated biomarker selected from the group consisting of Mast/stem cell growth factor receptor Kit (KIT), Leucine-rich alpha-2-glycoprotein (A2GL), Alpha-2-HS-glycoprotein (FETUA), Insulin-like growth factor I (IGF1), Chorionic somatomammotropin hormone 1 (CSH), Pregnancy-specific beta-1-glycoprotein 1 (PSG1), Pregnancy-specific beta-1-glycoprotein 11 (PSG11), Pregnancy-specific beta-1-glycoprotein 2 (PSG2), Pregnancy-specific beta-1-glycoprotein 3 (PSG3), Pregnancy-specific beta-1-glycoprotein 9 (PSG9), and Growth hormone variant (SOM2).

A method of detecting a reversal value for a pair of isolated biomarkers in a biological sample obtained from a pregnant female, the method comprising:

• (a) detecting the presence or amount of said pair of isolated biomarkers in said biological sample obtained from said pregnant female;
• and
• (b) measuring in said biological sample a reversal value for said pair of isolated biomarkers,
• wherein detecting comprises subjecting said biological sample to:
• (i) a proteomics work-flow comprised of mass spectrometry (MS) quantification:
• or (ii) an assay that utilizes a capture agent that binds to at least one biomarker of said pair of isolated biomarkers,
• wherein said biological sample is selected from the group consisting of whole blood, plasma, and serum, and
• wherein said pair of isolated biomarkers comprises Disintegrin and metalloproteinase domain-containing protein 12 (ADA12) and an isolated biomarker selected from the group consisting Mast/stem cell growth factor receptor Kit (KIT), Leucine-rich alpha-2-glycoprotein (A2GL), Alpha-2-HS-glycoprotein (FETUA), Insulin-like growth factor I (IGF1), Chorionic somatomammotropin hormone 1 (CSH), Pregnancy-specific beta-1-glycoprotein 1 (PSG1), Pregnancy-specific beta-1-glycoprotein 11 (PSG11), Pregnancy-specific beta-1-glycoprotein 2 (PSG2), Pregnancy-specific beta-1-glycoprotein 3 (PSG3), Pregnancy-specific beta-1-glycoprotein 9 (PSG9), and Growth hormone variant (SOM2).